Affinia Therapeutics
PrivateLast Round
Series C
Oct 7, 2025
Est. Valuation
$145M
Total Funding Raised
$210M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Affinia Therapeutics is a biotechnology company that develops next-generation gene therapies using a proprietary platform to engineer novel adeno-associated virus vectors for the treatment of rare and prevalent diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Affinia Therapeutics Comparables
Compare Affinia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Solid Biosciences Inc. | 83% | |
| Nuevocor | 81% | |
| Capsida Biotherapeutics | 79% |
Affinia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 7, 2025 | ||||
| Series B | May 3, 2021 | ||||
| Series A | Mar 31, 2020 |
Key People
Founding team and executive leadership
Affinia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| RA Capital Management | Series B |
| Farallon Capital Management | Series B |
| TCG Crossover | Series B |
| GV | Series C, Series B |
| Perceptive Advisors | Series C, Series B |
| New Enterprise Associates | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 85% MoM.
- Apr 28, 2026
Presenting data on AFTX-201 program for bag3-associated DCM at upcoming conference.
Affinia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Affinia Therapeutics's valuation, stock price, and market status.
Is Affinia Therapeutics a public or private company?
Affinia Therapeutics is a private company.
What is the current stock price of Affinia Therapeutics?
Affinia Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Affinia Therapeutics worth (valuation)?
Affinia Therapeutics's valuation is estimated at $145.0M based on funding round data.
Can I buy Affinia Therapeutics stock?
Affinia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Affinia Therapeutics's last funding round?
Affinia Therapeutics's most recent funding round was Series C on October 7, 2025.
Who are the main investors in Affinia Therapeutics?
Key investors in Affinia Therapeutics include EcoR1 Capital, Farallon Capital Management, New Enterprise Associates (NEA), F-Prime Capital, New Enterprise Associates.
Will Affinia Therapeutics IPO soon?
No public IPO plans have been announced for Affinia Therapeutics.
How can I track Affinia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Affinia Therapeutics's secondary market activity and sign up for updates.